NUTRACEA Form 10-Q August 11, 2008

| | S AND EXCHANGE COMMISSION |
|--|--|
| | Washington, D.C. 20549 |
| | FORM 10-Q |
| (Mark one) x QUARTERLY REPORT UNDER SECTION | N 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
| For the quarterly period ended June 30, 2008 | |
| o TRANSITION REPORT UNDER SECTION | N 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
| For the transition period from to | |
| Com | mission File Number 0-32565 |
| | NUTRACEA |
| (Exact Name of | Registrant as Specified in its Charter) |
| California | 87-0673375 |
| (State or other jurisdiction of | (I.R.S. Employer Identification No.) |
| incorporation or organization) | |
| 5090 North 40th St., Suite 400 | 85018 |
| Phoenix, AZ | (Zip Code) |
| (Address of Principal Executive Offices) | |

Issuer's telephone number, including area code: (602) 522-3000

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of "large accelerated filer:, "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange.

Large accelerated filer o Accelerated filer x

Non-accelerated filer o (do not check if a smaller reporting company) Smaller reporting company o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

APPLICABLE ONLY TO CORPORATE ISSUERS

| State the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practiculate: 167,993,724 as of August 6, 2008. | cable |
|---|-------|
| late. 107,773,724 as of August 0, 2006. | |
| | |
| | |

FORM 10-Q

Index

| PART I. | FINANCIAL INFORMATION | |
|----------------|--|----|
| Item 1. | Financial Statements | |
| | (a) Consolidated Condensed Balance Sheets at June 30, 2008 (Unaudited) and December 31, 2007 | 4 |
| | (b) Consolidated Condensed Statements of Operations for the three and six months ended June 30, 2008 and 2007 (Unaudited) | 5 |
| | (c) Consolidated Condensed Statements of Comprehensive (Loss) Income for the three and six months ended June 30, 2008 and 2007 (Unaudited) | 6 |
| | (d) Consolidated Condensed Statements of Cash Flows for the six months ended June 30, 2008 and 2007 (Unaudited) | 7 |
| | (e) Notes to Unaudited Consolidated Condensed Financial Statements | 9 |
| Item 2. | Management's Discussion and Analysis of Financial Condition and Results of Operations | 27 |
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 38 |
| Item 4. | Controls and Procedures | 38 |
| PART II. | OTHER INFORMATION | 39 |
| Item 1. | Legal Proceedings | 39 |
| Item 1A. | Risk Factors | 39 |
| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 46 |
| Item 3. | Defaults Upon Senior Securities | 46 |
| Item 4. | Submission of Matters to a Vote of Security Holders | 46 |
| Item 5. | Other Information | 47 |
| Item 6. | Exhibits | 48 |
| Signatures | | 49 |
| Certifications | | |

FORWARD-LOOKING STATEMENTS

This quarterly report on Form 10-Q contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws, including, but not limited to, any projections of earnings, revenue or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements concerning proposed new services or developments; any statements regarding future economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing.

Forward-looking statements may include the words "may," "could," "will," "estimate," "intend," "continue," "believe," "e "anticipate" or other similar words. The forward-looking statements contained herein reflect our current views with respect to future events and are subject to certain risks, uncertainties and assumptions. Actual results may differ materially from those projected in such forward-looking statements due to a number of factors, risks and uncertainties, including the factors that may affect future results set forth in this Current Report on Form 10-Q and in our annual Report on Form 10-K for the year ended December 31, 2007. We disclaim any obligation to update any forward looking statements as a result of developments occurring after the date of this quarterly report.

3

PART 1. FINANCIAL INFORMATION

Item 1. Financial Statements

NUTRACEA AND SUBSIDIARIES CONSOLIDATED CONDENSED BALANCE SHEETS

| | | June 30, 2008 (Unaudited) |] | December 31, 2007 |
|--|----|---|----|---|
| ASSETS | | (Unaudited) | | |
| Current assets: | | | | |
| Cash and cash equivalents | \$ | 16,067,000 | \$ | 41,298,000 |
| Restricted cash | Ψ | 906,000 | Ψ | 758,000 |
| Trade accounts receivable, net of allowance for doubtful accounts of | | , 00,000 | | 700,000 |
| \$3,177,000 and \$2,999,000, respectively | | 4,270,000 | | 2,346,000 |
| Inventories | | 4,947,000 | | 1,808,000 |
| Notes receivable, net of allowance for doubtful notes receivable of | | , , , , , , , , | | ,, |
| \$573,000 and \$250,000, respectively | | 858,000 | | 2,936,000 |
| Deposits and other current assets | | 2,828,000 | | 2,545,000 |
| - · F | | _,,,,, | | _,_ 1,_ 1,_ 1,_ 1 |
| Total current assets | | 29,876,000 | | 51,691,000 |
| | | ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | | ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, |
| Restricted cash | | 3,248,000 | | 1,791,000 |
| Notes receivable, net of current portion | | - | | 5,039,000 |
| Property and equipment, net | | 43,317,000 | | 19,328,000 |
| Investment in joint ventures | | 11,786,000 | | 1,191,000 |
| Patents and trademarks, net of accumulated amortization | | 5,349,000 | | 5,743,000 |
| Other non-current | | 132,000 | | - |
| Goodwill | | 52,668,000 | | 39,510,000 |
| | | | | |
| Total assets | \$ | 146,376,000 | \$ | 124,293,000 |
| | | | | |
| LIABILITIES AND SHAREHOLDERS' EQUITY | | | | |
| Current liabilities: | | | | |
| Accounts payable and accrued liabilities | \$ | 14,863,000 | \$ | 7,506,000 |
| Deferred revenue | | 12,000 | | 90,000 |
| Note payable | | 23,000 | | 23,000 |
| • • | | | | |
| Total current liabilities | | 14,898,000 | | 7,619,000 |
| | | | | |
| Long-term liabilities: | | | | |
| Long-term liabilities | | 7,350,000 | | - |
| Notes payable, net of current portion | | 64,000 | | 77,000 |
| Total liabilities | | 22,312,000 | | 7,696,000 |
| Commitments and contingencies | | | | |
| Shareholders' equity: | | | | |
| Common stock, no par value, 350,000,000 shares authorized, | | 198,623,000 | | 177,813,000 |
| Common stock, no par value, 550,000,000 shares authorized, | | 170,023,000 | | 177,013,000 |

167,744,000 and 144,108,000 shares issued and outstanding

| Accumulated deficit | (74,061,000) | (61,216,000) |
|--|----------------------|--------------|
| Foreign currency cumulative translation gain | (498,000) | - |
| Total shareholders' equity | 124,064,000 | 116,597,000 |
| | | |
| Total liabilities and shareholder's equity | \$ 146,376,000 \$ | 124,293,000 |

The accompanying notes are an integral part of these consolidated condensed financial statements.

4

NUTRACEA AND SUBSIDIARIES CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS (Unaudited)

| | ree Months Ended ine 30, 2008 | Three Months Ended June 30, 2007 | | Six Months Ended June 30, 2008 | | Six Months Ended June 30, 2007 | |
|---------------------------------------|-------------------------------------|--|----|--------------------------------------|----|--------------------------------------|--|
| Revenues: | | | | | | | |
| Product sales | \$ 10,314,000 | \$ 7,996,000 | \$ | 15,425,000 | \$ | 9,993,000 | |
| Licensing fees | - | 5,000,000 | | - | | 5,000,000 | |
| Total revenue | 10,314,000 | 12,996,000 | | 15,425,000 | | 14,993,000 | |
| | | | | | | | |
| Cost of sales | 7,277,000 | 3,863,000 | | 12,071,000 | | 4,976,000 | |
| | | | | | | | |
| Gross profit | 3,037,000 | 9,133,000 | | 3,354,000 | | 10,017,000 | |
| | | | | | | | |
| Operating expenses | | | | | | | |
| Research and development expenses | 738,000 | 170,000 | | 1,002,000 | | 291,000 | |
| Selling, general and administrative | | | | | | | |
| expenses | 5,871,000 | 5,657,000 | | 11,049,000 | | 7,970,000 | |
| Professional fees | 1,125,000 | 1,536,000 | | 3,083,000 | | 1,995,000 | |
| Total operating expenses | 7,734,000 | 7,363,000 | | 15,134,000 | | 10,256,000 | |
| | | | | | | | |
| (Loss) income from operations | (4,697,000) | 1,770,000 | | (11,780,000) | | (239,000) | |
| | | | | | | | |
| Other income (expense) | | | | | | | |
| Interest income | 161,000 | 876,000 | | 421,000 | | 1,388,000 | |
| Interest expense | (365,000) | - | | (485,000) | | - | |
| Gain on settlement | - | - | | - | | 1,250,000 | |
| Loss on disposal of assets | (331,000) | (309,000) | | (331,000) | | (309,000) | |
| Other expenses | (586,000) | - | | (341,000) | | - | |
| Loss on equity investment | (63,000) | (250,000) | | (80,000) | | (250,000) | |
| Total (loss) income before income tax | (5,881,000) | 2,087,000 | | (12,596,000) | | 1,840,000 | |
| | | | | | | | |
| Income tax expense | (282,000) | (85,000) | | (319,000) | | (85,000) | |
| Net (loss) income from continuing | | | | | | | |
| operations | (6,163,000) | 2,002,000 | | (12,915,000) | | 1,755,000 | |
| | | | | | | | |
| Minority interest | 70,000 | - | | 70,000 | | _ | |
| Net (loss) income | \$ (6,093,000) | 2,002,000 | \$ | (12,845,000) | \$ | 1,755,000 | |
| | | | | | | | |
| Basic and diluted (loss) earnings per | | | | | | | |
| share: | | | | | | | |
| Basic (loss) income per share | \$ (0.04) | 0.01 | \$ | (0.09) | | 0.01 | |
| Fully diluted (loss) income per share | \$ (0.04) | \$ 0.01 | \$ | (0.09) | \$ | 0.01 | |
| Weighted average basic number of | | | | | | | |
| shares outstanding | 151,867,000 | 136,257,000 | | 145,545,000 | | 118,952,000 | |
| Weighted average diluted number of | | | | | | | |
| shares outstanding | 151,867,000 | 167,259,000 | | 145,545,000 | | 148,954,000 | |
| | | | | | | | |

The accompanying notes are an integral part of these consolidated condensed financial statements.

5